A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Recruiting now · Phase 1

Conditions studied: Solid Tumors, Hematologic Malignancies

In brief

A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.

Key facts

Study ID

NCT07195916

Run by

Incyte Corporation

People needed

280

Starts

2026-01-08

Expected to finish

2028-08-18

Last updated by the study team

2026-08-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years.
• ECOG performance status of 0 or 1.
• Histologically confirmed:
• Clear cell renal cell carcinoma (ccRCC).
• Diffuse large B-cell lymphoma (DLBCL, NOS).
• High-grade B-cell lymphoma (HGBCL).
• Peripheral T-cell lymphoma (PTCL, incl. NOS and ALCL).
• Cutaneous T-cell lymphoma (CTCL, incl. MF or SS ≥Stage IIB with B0/B1 blood involvement).
• Disease progression, relapse, or refractory to prior therapy:
• ccRCC: ≥1 prior line incl. ICI + TKI.
• DLBCL/HGBCL: ≥2 prior lines incl. immunochemotherapy and salvage.
• PTCL/CTCL: ≥1 prior systemic therapy.
• Measurable disease by RECIST v1.1 (ccRCC), Lugano 2014 (lymphomas), or ISCL/USCLC/EORTC (CTCL).
• Tumor tissue available for central testing.

You may not qualify if…

• Untreated or progressive CNS disease unless previously treated and stable.
• Other active invasive malignancy within 2 years (except certain low-risk cancers).
• Prior CD70-targeting therapy, including CAR T.
• ASCT or CAR T ≤12 weeks before enrollment; prior organ or allogeneic transplant.
• Unresolved ≥Grade 2 toxicity from prior therapy (with exceptions).
• Primary immunodeficiency or active autoimmune disease requiring immunosuppression.
• Active HBV, HCV, HIV, or other chronic infections requiring systemic therapy.
• Pregnancy, breastfeeding, or unwillingness to use effective contraception.
• Other protocol-defined Inclusion/Exclusion Criteria may apply.

Where it is running

• City of Hope Medical Center — Duarte, California, United States (enrolling)
• The University of Nebraska Medical Center — Omaha, Nebraska, United States (enrolling)
• Scri Oncology Partners — Nashville, Tennessee, United States (enrolling)
• Md Anderson Cancer Center — Houston, Texas, United States (enrolling)
• Macquarie University Hospital — Sydney, New South Wales, Australia (enrolling)
• Princess Alexandra Hospital Australia — Woolloongabba, Queensland, Australia (enrolling)
• Cancer Research Sa — Adelaide, South Australia, Australia (enrolling)
• Peter Maccallum Cancer Centre-Royal Melbourne Hospital — Melbourne, Victoria, Australia (enrolling)
• Universitair Ziekenhuis Leuven — Leuven, Belgium (enrolling)
• Aou Policlinico S. Orsola-Malpighi — Bologna, Italy
• Fondazione Irccs Istituto Nazionale Dei Tumori — Milan, Italy
• Policlinico Universitario Agostino Gemelli Universita Cattolica Del Sacro Cuore — Rome, Italy
• Cliniques Universitaires Ucl Saint-Luc — Brussels, Belgium
• Universitair Ziekenhuis Antwerpen — Edegem, Belgium
• University of California San Diego Medical Center, Moores Cancer Center — La Jolla, California, United States
• University of Michigan — Ann Arbor, Michigan, United States
• Universitair Ziekenhuis Gent (Uz Gent) — Ghent, Belgium
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Centro Ricerche Cliniche Di Verona — Verona, Italy
• Vanderbilt Medical Center — Nashville, Tennessee, United States
• Aarhus University Hospital — Aarhus, Denmark
• Rigshospitalet Uni of Hospital of Copenhagen — Copenhagen, Denmark

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.